BAPST. A Combo of Common use drugs as metabolic therapy of cancer-a theoretical proposal

Advances in cancer therapy have yet to impact worldwide cancer mortality. Poor cancer drug affordability is one of the factors limiting mortality burden strikes. Up to now, cancer drug repurposing had no meet expectations concerning drug affordability. The three FDA-approved cancer drugs developed under repurposing -all-trans-retinoic acid, arsenic trioxide, and thalidomide- do not differ in price from other drugs developed under the classical model. Though additional factors affect the whole process from inception to commercialization, the repurposing of widely used, commercially available, and cheap drugs may help. This work reviews the concept of the malignant metabolic phenotype and its exploitation by simultaneously blocking key metabolic processes altered in cancer. We elaborate on a combination called BAPST, which stands for the following drugs and pathways they inhibit: Benserazide (glycolysis), Apomorphine (glutaminolysis), Pantoprazole (Fatty-acid synthesis), Simvastatin (mevalonate pathway), and Trimetazidine (Fatty-acid oxidation). Their respective primary indications are: • Parkinson's disease (benserazide and apomorphine). • Peptic ulcer disease (pantoprazole). • Hypercholesterolemia (simvastatin). • Ischemic heart disease (trimetazidine). When used for their primary indication, the literature review on each of these drugs shows they have a good safety profile and lack predicted pharmacokinetic interaction among them. Most importantly, the inhibitory enzymatic concentrations required for inhibiting their cancer targets enzymes are below the plasma concentrations observed when these drugs are used for their primary indication. Based on that, we propose that the regimen BAPTS merits preclinical testing.

[Epidemiologic aspects of snakebites in Vale do Ribeira, São Paulo, 1985-1989]

This study reports on the incidence of snakebites from January 1985 to December 1989 in Vale do Ribeira, S o Paulo, Brazil. Overall incidence ranged from 68.7 to 84.2/100,000. There were 840 snakebites during this period, with higher frequency from October to May. The highest incidence rates were observed in the districts of Jugui and Eldorado (159.4 and 131.4/100,000, respectively). Most of the patients were male. Agricultural workers were the most heavily affected. Most of the patients received treatment within 2 hours after the bite. Morbidity was not severe and lethality was 0.2%.

Critical Care Scoring System--new concept based on hemodynamic data

Based on the rationale that hemodynamic, oxygen transport, and perfusion derangements describe physiologically important abnormalities in critically ill patients, we devised a Critical Care Scoring System (CCSS). The database includes a retrospective analysis of 318 patients managed with pulmonary artery catheters during 1986 to 1988. For comparison, Acute Physiology and Chronic Health Evaluation (APACHE II) score was computed for these patients. CCSS includes a total of 17 variables with a weighted score of 71. The mortality rates for increases by 5 points were observed and were statistically significant (p less than .0001). The same was not true for APACHE II. Although neither of the scores could predict ICU days, both reflected the number of life-threatening complications. Serial CCSS that was computed at 24 +/- 4 h (CCSS-C) provided documentation for improvement in patient condition secondary to therapeutic interventions. Statistically improved mortality prediction was observed with CCSS-C. Since 70 (45.7%) of 153 patients died with an APACHE II score less than 14, it appears that this score is deficient in a specific group of patients, i.e., those requiring invasive monitoring. For patients with circulatory or respiratory failure, CCSS may offer a better tool to predict mortality and evaluate therapy.